Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

NCT01988077 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER_GOV

Sponsor class

Stopped due to toxicity of cyclophosphamide

Conditions

A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response

Interventions

BIOLOGICAL: Adoptive cell transfer
DRUG: Ipilimumab 5 MG/ML Injection [Yervoy]

Sponsor

Sheba Medical Center